['dermatitis, atopic']
['an2728 topical ointment, 2%', 'matching vehicle control']

        Inclusion Criteria:

          -  Males or females 2 years and older

          -  Has a clinical diagnosis of AD according to the criteria of Hanifin and Rajka

          -  Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)

          -  Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1

          -  All female subjects of childbearing potential must use acceptable methods of
             contraception from the Screening Visit continuously until 30 days after stopping study
             drug

        Exclusion Criteria:

          -  As determined by the study doctor, a medical history that may interfere with study
             objectives

          -  Unstable AD or any consistent requirement for high potency topical corticosteroids

          -  History of use of biologic therapy (including intravenous immunoglobulin)

          -  Recent or anticipated concomitant use of systemic or topical therapies that might
             alter the course of AD

          -  Recent or current participation in another research study

          -  Females who are breastfeeding, pregnant, or with plans to get pregnant during the
             participation in the study

          -  Participation in a previous AN2728 clinical trial
      